Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III registration study of topsalysin in localized prostate cancer.

Trial Profile

Phase III registration study of topsalysin in localized prostate cancer.

Planning
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2018

At a glance

  • Drugs Topsalysin (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Sophiris Bio
  • Most Recent Events

    • 02 Dec 2018 According to a Sophiris Bio media release, the Company believes that the data generated in the single-administration portion of the Phase 2b prostate cancer study supports the advancement of the program into this single Phase 3 pivotal trial.
    • 13 Nov 2018 According to a Sophiris Bio media release, the Company is in the process of preparing information for regulatory guidance meetings with the U.S. Food and Drug Administration and the European Medicines Agency which are expected to take place in the first half of 2019, after which the Company will provide an update on the Phase 3 trial design
    • 11 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top